Fig 1.
Flow chart illustrating patient selection process.
Table 1.
Patient characteristics.
Fig 2.
Fagan nomogram illustrating the pre-test probability of residual disease after treatment (prevalence), set at 30%, and the post-test probability after a negative (dotted line) or positive (solid line) FDG-PET/CT scan.
Fig 3.
Time dependency of sensitivity and specificity.
Fig 4.
Accuracy depending on the time interval between FDG-PET/CT and the end of therapy.
The solid line interval of this model. Real observations from our data (with two week-intervals) are depicted by the dots. The solid line represents the binary logistic regression model. The dotted line represents the 95%-confidence intervals.
Fig 5.
Kaplan-Meier survival curve illustrating the survival of patients with an FDG-PET/CT negative (solid) or positive (dotted) for residual disease.
The intersection with the 50% reference line marks the median survival. In a multivariable Cox regression model adjusting for age, sex and tumor stage, a positive FDG-PET/CT was associated with an almost eightfold higher risk of death (HR 7.9; 95% CI 4.0–15.9; p<0.001).